The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled ...

Bioluminescent luciferase enzymes have historically been too dim to use as probes in living tissue. But recent advances have ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Avidity Biosciences (RNA) announced the completion of enrollment in the biomarker cohort in the Phase 1/2 Fortitude clinical trial of ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

The Republic aims to strengthen its RNA capabilities by providing a platform for key institutions here to collaborate. Read ...